Current medical therapy for pulmonary arterial hypertension

Abstract

Pulmonary arterial hypertension therapies that are currently available target one of three major pathways implicated in pulmonary arterial hypertension pathogenesis and progression: nitric oxide, endothelin-1, and prostacyclin. The development and approval of more than a dozen targeted therapies is a result of a closely collaboration between pharmaceutical companies, clinical researchers and patients. A review of data and experience with pulmonary arterial hypertension drugs are reported here.